Home » Stocks » HZNP

Horizon Therapeutics PLC (HZNP)

Stock Price: $70.05 USD -0.10 (-0.14%)
Updated November 23, 4:00 PM EST - Market closed
After-hours: $70.14 +0.09 (0.13%) Nov 23, 5:22 PM

Stock Price Chart

Key Info

Market Cap 15.46B
Revenue (ttm) 1.82B
Net Income (ttm) 792.01M
Shares Out 220.71M
EPS (ttm) 3.61
PE Ratio 19.40
Forward PE 19.80
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 23
Last Price $70.05
Previous Close $70.15
Change ($) -0.10
Change (%) -0.14%
Day's Open 69.80
Day's Range 68.98 - 70.82
Day's Volume 2,394,403
52-Week Range 23.81 - 86.67

More Stats

Market Cap 15.46B
Enterprise Value 14.73B
Earnings Date (est) Mar 3, 2021
Ex-Dividend Date n/a
Shares Outstanding 220.71M
Float 217.94M
EPS (basic) 4.13
EPS (diluted) 3.61
FCF / Share 0.93
Dividend n/a
Dividend Yield n/a
Earnings Yield 5.15%
FCF Yield 1.28%
Payout Ratio n/a
Shares Short 5.13M
Short Ratio 2.47
Short % of Float 2.35%
Beta 1.33
PE Ratio 19.40
Forward PE 19.80
P/FCF Ratio 78.35
PS Ratio 8.50
PB Ratio 4.07
Revenue 1.82B
Operating Income 305.67M
Net Income 792.01M
Free Cash Flow 197.32M
Net Cash 726.13M
Net Cash / Share 3.29
Gross Margin 51.57%
Operating Margin 16.81%
Profit Margin 43.50%
FCF Margin 10.85%
ROA 4.03%
ROE 29.60%
ROIC 14.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (11)

Buy 10
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$105.55*
(50.68% upside)
Low
85.0
Current: $70.05
High
123.0
Target: 105.55
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1,3001,2081,05698175729774.0218.846.932.38
Revenue Growth7.66%14.33%7.66%29.6%154.94%301.2%292.78%172.04%191.54%-
Gross Profit93881656358953821859.396.97-0.34-1.89
Operating Income12638.75-339-13945.08-8.49-42.85-78.87-121-43.75
Net Income573-38.38-350-16639.53-264-149-87.79-113-27.07
Shares Outstanding18316616316114983.7563.6638.879.011.28
Earnings Per Share2.90-0.23-2.15-1.030.25-3.15-2.34-2.26-12.56-21.16
Operating Cash Flow42619528436919427.55-54.29-76.64-41.54-37.53
Capital Expenditures-17.8639.65-4.34-15.73-7.16-3.50-1.20-1.34-1.60-0.71
Free Cash Flow40823428035418724.05-55.49-77.98-43.14-38.25
Cash & Equivalents1,08096275851686122081.2210518.725.58
Total Debt1,3531,8971,9021,8071,13734611148.8019.4424.62
Net Cash / Debt-273-935-1,144-1,291-275-126-29.5456.09-0.72-19.03
Assets4,4363,9424,2024,2923,0591,114253194101162
Liabilities2,2512,7523,2013,0281,74557430288.0155.1764.63
Book Value2,1851,1901,0011,2641,313540-49.0810645.9197.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Horizon Therapeutics PLC
Country Ireland
Employees 1,275
CEO Timothy P. Walbert

Stock Information

Ticker Symbol HZNP
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NASDAQ: HZNP
IPO Date July 28, 2011

Description

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.